160 related articles for article (PubMed ID: 29760870)
1. A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma.
Bui N; Kamat N; Ravi V; Chawla S; Lohman M; Ganjoo KN
Rare Tumors; 2018; 10():2036361318771771. PubMed ID: 29760870
[TBL] [Abstract][Full Text] [Related]
2. Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.
Saloustros E; Nikolaou M; Kalbakis K; Polyzos A; Christofillakis C; Kentepozidis N; Pistamaltzian N; Kourousis C; Vamvakas L; Georgoulias V; Mavroudis D
Clin Breast Cancer; 2018 Feb; 18(1):88-94. PubMed ID: 29153775
[TBL] [Abstract][Full Text] [Related]
3. Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
Saji S; Taira N; Kitada M; Takano T; Takada M; Ohtake T; Toyama T; Kikawa Y; Hasegawa Y; Fujisawa T; Kashiwaba M; Ishida T; Nakamura R; Yamamoto Y; Toh U; Iwata H; Masuda N; Morita S; Ohno S; Toi M
Lancet Oncol; 2022 May; 23(5):636-649. PubMed ID: 35405087
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.
Ray-Coquard IL; Domont J; Tresch-Bruneel E; Bompas E; Cassier PA; Mir O; Piperno-Neumann S; Italiano A; Chevreau C; Cupissol D; Bertucci F; Bay JO; Collard O; Saada-Bouzid E; Isambert N; Delcambre C; Clisant S; Le Cesne A; Blay JY; Penel N
J Clin Oncol; 2015 Sep; 33(25):2797-802. PubMed ID: 26215950
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
Penel N; Bui BN; Bay JO; Cupissol D; Ray-Coquard I; Piperno-Neumann S; Kerbrat P; Fournier C; Taieb S; Jimenez M; Isambert N; Peyrade F; Chevreau C; Bompas E; Brain EG; Blay JY
J Clin Oncol; 2008 Nov; 26(32):5269-74. PubMed ID: 18809609
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
Honecker F; Kollmannsberger C; Quietzsch D; Haag C; Schroeder M; Spott C; Hartmann JT; Baronius W; Hempel V; Kanz L; Bokemeyer C
Anticancer Drugs; 2002 Jun; 13(5):497-503. PubMed ID: 12045461
[TBL] [Abstract][Full Text] [Related]
7. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
Chan JK; Brady MF; Penson RT; Huang H; Birrer MJ; Walker JL; DiSilvestro PA; Rubin SC; Martin LP; Davidson SA; Huh WK; O'Malley DM; Boente MP; Michael H; Monk BJ
N Engl J Med; 2016 Feb; 374(8):738-48. PubMed ID: 26933849
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
[TBL] [Abstract][Full Text] [Related]
9. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.
Ferrero JM; Hardy-Bessard AC; Capitain O; Lortholary A; Salles B; Follana P; Herve R; Deblock M; Dauba J; Atlassi M; Largillier R
Cancer; 2016 Oct; 122(20):3119-3126. PubMed ID: 27412268
[TBL] [Abstract][Full Text] [Related]
10. A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer.
Friedland DM; Dakhil S; Hollen C; Gregurich MA; Asmar L
Cancer Invest; 2004; 22(3):374-82. PubMed ID: 15493358
[TBL] [Abstract][Full Text] [Related]
11. A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer.
Zhao M; Pan X; Layman R; Lustberg MB; Mrozek E; Macrae ER; Wesolowski R; Carothers S; Puhalla S; Shapiro CL; Ramaswamy B
Invest New Drugs; 2014 Dec; 32(6):1285-94. PubMed ID: 24894652
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial.
Lebellec L; Bertucci F; Tresch-Bruneel E; Ray-Coquard I; Le Cesne A; Bompas E; Blay JY; Italiano A; Mir O; Ryckewaert T; Toiron Y; Camoin L; Goncalves A; Penel N; Le Deley MC
BMC Cancer; 2018 Oct; 18(1):963. PubMed ID: 30305054
[TBL] [Abstract][Full Text] [Related]
13. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.
O'Malley DM; Richardson DL; Rheaume PS; Salani R; Eisenhauer EL; McCann GA; Fowler JM; Copeland LJ; Cohn DE; Backes FJ
Gynecol Oncol; 2011 May; 121(2):269-72. PubMed ID: 21315428
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Gonzalez-Martin A; Gladieff L; Tholander B; Stroyakovsky D; Gore M; Scambia G; Kovalenko N; Oaknin A; Ronco JP; Freudensprung U; Pignata S;
Eur J Cancer; 2013 Dec; 49(18):3831-8. PubMed ID: 24007819
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.
Perez DG; Suman VJ; Fitch TR; Amatruda T; Morton RF; Jilani SZ; Constantinou CL; Egner JR; Kottschade LA; Markovic SN
Cancer; 2009 Jan; 115(1):119-27. PubMed ID: 19090009
[TBL] [Abstract][Full Text] [Related]
17. Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial.
Ray-Coquard I; Harter P; Lorusso D; Dalban C; Vergote I; Fujiwara K; Gladieff L; Lück HJ; Floquet A; Chevalier-Place A; Schnelzer A; Pignata S; Selle F; Sehouli J; Brocard F; Mangili G; Pautier P; De Giorgi U; Provansal M; Heudel PE
JAMA Oncol; 2020 Dec; 6(12):1923-1930. PubMed ID: 33030515
[TBL] [Abstract][Full Text] [Related]
18. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
Symonds L; Linden H; Gadi V; Korde L; Rodler E; Gralow J; Redman M; Baker K; Wu QV; Jenkins I; Kurland B; Garrison M; Smith J; Anderson J; Van Haelst C; ; Specht J
Clin Breast Cancer; 2019 Apr; 19(2):e283-e296. PubMed ID: 30737173
[TBL] [Abstract][Full Text] [Related]
19. Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study.
Cortot AB; Audigier-Valette C; Molinier O; Le Moulec S; Barlesi F; Zalcman G; Dumont P; Pouessel D; Poulet C; Fontaine-Delaruelle C; Hiret S; Dixmier A; Renault PA; Becht C; Raffy O; Dayen C; Mazieres J; Pichon E; Langlais A; Morin F; Moro-Sibilot D; Besse B
Eur J Cancer; 2020 May; 131():27-36. PubMed ID: 32276179
[TBL] [Abstract][Full Text] [Related]
20. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin.
Krasner CN; Castro C; Penson RT; Roche M; Matulonis UA; Morgan MA; Drescher C; Armstrong DK; Wolfe JK; Lee H; Supko JG; Seiden M; Birrer MJ; Dizon DS
Gynecol Oncol; 2019 May; 153(2):223-229. PubMed ID: 30765148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
